Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: oreja guevara c. Brain. 2024 Dec 21:awae409. doi: 10.1093/brain/awae409. Online ahead of print. Brain. 2024. PMID: 39707906
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab.
Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C, Lin CJ, Ferreira G, Craveiro L, Zecevic D, Pasquarelli N, Hellwig K. Vukusic S, et al. Among authors: oreja guevara c. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200349. doi: 10.1212/NXI.0000000000200349. Epub 2024 Dec 17. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39689270 Free PMC article.
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
Carvajal R, Rodríguez-Acevedo B, García-Vasco L, Zabalza A, Ariño H, Bollo L, Cabello-Clotet N, Castilló J, Cobo-Calvo Á, Comabella M, Falcó-Roget A, Galán I, García-Sarreón A, Gómez-Estévez I, Granados G, La Puma D, Mato Chain G, Midaglia L, Nieto-García A, Otero-Romero S, Pappolla A, Rodriguez M, Sansano I, Río J, Tagliani P, Tur C, Vidal-Jordana Á, Vilaseca A, Villar A, Sastre-Garriga J, Oreja-Guevara C, Tintoré M, Montalban X, Arrambide G. Carvajal R, et al. Among authors: oreja guevara c. Mult Scler. 2024 Dec;30(14):1788-1801. doi: 10.1177/13524585241297038. Epub 2024 Nov 9. Mult Scler. 2024. PMID: 39520297
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.
Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE. Oreja-Guevara C, et al. Ther Adv Neurol Disord. 2024 Oct 16;17:17562864241284372. doi: 10.1177/17562864241284372. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39483817 Free PMC article. Review.
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.
Aguirre C, Alonso-Torres A, Agüera E, García-Domínguez JM, Montero-Escribano P, González-Quintanilla V, Costa-Frossard L, Oreja-Guevara C, Reyes-Garrido V, Caminero-Rodríguez AB, Riancho J, Sánchez O, Forero L, Pérez-Parra F, Ares-Luque A, Téllez N, Arzalluz-Luque J, Iglesias F, Casado-Ruiz V, Castellano-Vicente AJ, Borrega L, Galán V, de Antonio LAR, Romero C, García-Rodríguez R, Cano-Orgaz AT, Sánchez-Menoyo JL, Pérez-Ruiz D, Gutiérrez-Martin F, Hernández-Echevarría L, Meca-Lallana V. Aguirre C, et al. Among authors: oreja guevara c. Clin Drug Investig. 2024 Nov;44(11):829-838. doi: 10.1007/s40261-024-01397-5. Epub 2024 Oct 28. Clin Drug Investig. 2024. PMID: 39466585
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, Guasp M, Naranjo L, Ruiz-García R, Caballero E, González-Álvarez V, Delgadillo V, Romeu G, Del-Prado-Sánchez C, Cabrera-Maqueda JM, Benito-León J, Iñiguez C, Garcia-Dominguez JM, Calles C, Cano A, Álvarez-Bravo G, González-Suárez I, Oreja-Guevara C, Ros M, Millan-Pascual J, Meca-Lallana JE, Borrega Canelo L, Martín-Martínez J, Palao M, Gracia J, Villaverde-González R, Llufriu S, Blanco Y, Saiz A, Dalmau J, Sepulveda M, Armangue T; Spanish MOGAD study group. Fonseca E, et al. Among authors: oreja guevara c. Neurology. 2024 Sep 24;103(6):e209682. doi: 10.1212/WNL.0000000000209682. Epub 2024 Aug 27. Neurology. 2024. PMID: 39190859
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium*. Arnett S, et al. J Neurol. 2024 Aug;271(8):4794-4812. doi: 10.1007/s00415-024-12452-8. Epub 2024 Jul 3. J Neurol. 2024. PMID: 38958756 Free PMC article. Review.
Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores.
Lin TY, Motamedi S, Asseyer S, Chien C, Saidha S, Calabresi PA, Fitzgerald KC, Samadzadeh S, Villoslada P, Llufriu S, Green AJ, Preiningerova JL, Petzold A, Leocani L, Garcia-Martin E, Oreja-Guevara C, Outteryck O, Vermersch P, Balcer LJ, Kenney R, Albrecht P, Aktas O, Costello F, Frederiksen J, Uccelli A, Cellerino M, Frohman EM, Frohman TC, Bellmann-Strobl J, Schmitz-Hübsch T, Ruprecht K, Brandt AU, Zimmermann HG, Paul F. Lin TY, et al. Among authors: oreja guevara c. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200269. doi: 10.1212/NXI.0000000000200269. Epub 2024 Jun 28. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38941572 Free PMC article.
229 results